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PRAbstractNeuropsychological deficits, such as poor episodic memory, are consistent features of mild cognitive impairment and also that of early stage of
dementia. The aim of the present study was to detect cognitive dysfunction among patients with Alzheimer's disease or with mild cognitive
impairment (MCI), which refers to a transitional state between the cognition of normal aeging and mild dementia regarded as a high-risk condition
for the development of clinically probable Alzheimer's disease (AD). Computerized tests of memory, attention and executive functions were
studied in groups of AD subjects (n=15) and MCI subjects (n=25). On all measures, the performance of the AD group was significantly weaker
compared to healthy individuals or to the MCI group. The performance of both the AD and MCI patients in the Paired Associate Learning test was
significantly impaired, which may suggest that MCI patients are already in the early stages of the disease.











RR1. IntroductionMild cognitive impairment (MCI) is a widely cited concept inclinical research on ageing-related cognitive disorder. Generally,
it refers to subclinical complaints of memory functioning in
elderly people, which are considered to have a high probability
of evolving towards Alzheimer's disease (AD). Cognitive
impairment without dementia is so common among elderly
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describe this end of the normal cognitive range, such as benign
senescent forgetfulness (Kral, 1962), age-associated memory
impairment (Crook et al., 1986), mild cognitive decline (ICD-
10, 1993), mild neurocognitive decline (DSM IV, 1994), and
mild cognitive impairment (Petersen et al., 1997; De Carli,
2003). Benign senescent forgetfulness was one of the earliest
terms to denote a stable impairment, commonly featuring
depressive symptoms (Kral, 1962). On the other hand, age-
associated memory impairment refers to subjective complaints
of memory loss in elderly people, verified by a decrease of at
least one standard deviation (SD) in a formal memory test in
comparison with means established for young adults (Crook
et al., 1986). This termwas criticised by Levy and his colleagues,
who found that age-associated memory impairment was a
concept too restrictive in terms of the nature of the deficit and
pointed out that cognitive impairment itself commonly occurs
with other deficits. They proposed the term “ageing-associated
cognitive decline” with a wider range of cognitive functions,
such as attention, memory, learning, thinking, language and











































































































Mean characteristics of the patient groups t1:2
t1:3Patient groups Mean age±S.D. MMSE score mean±S.D. CDR mean±S.D.
t1:4AD (n=15) 58±6 21±1.2 2.1±1.3
t1:5MCI (n=25) 55±6 28±0.6 0.5





decline in cognitive functioning due to the physiological process
of ageing (Levy, 1994).Within ICD-10, the criteria given for mild
cognitive disorder refer to disorders of memory, learning and
concentration (ICD-10, 1993). DSM-IV proposed a similar entity,
“mild neurocognitive disorder”, which also encompasses percep-
tual-motor, linguistic and central executive functions besides
memory and learning difficulties (DSM-IV, 1994). Petersen and
his colleagues initially used the term to refer to complaints of
memory loss with normal general cognitive functioning and
retained ability to carry out activities of daily living (Petersen et
al., 1997). Ritchie and his colleagues examined whether this type
of cognitive deficit was partly due to an underlying disease which
might be differentiated from normal ageing-related physiological
changes. They reviewed the conceptual basis and current clinical
status of mild cognitive impairment and concluded that MCI was
based on a pathological model of cognitive change, it was
applicable to cognitive impairment only in elderly people, and it
was not generally thought to be a direct consequence of a systemic
disease, rather a risk factor for senile dementia (Ritchie and
Touchon, 2000). Other authors defined MCI as a prodrome of
Alzheimer's disease or a clinically heterogeneous group of
patients at increased risk of dementia due to any cause. Morris
(2005) suggested that MCI in many cases represents a transitional
state between normal cognition and AD. The most common
subset of subjects withMCI are patients with amnestic MCI, who
present with a subjective memory complaint, preferably corrob-
orated by an informant, and have an objective memory
impairment compared with age-matched healthy subjects.
However, they perform well in tests of general cognitive function
and have generally preserved activities of daily living. Neverthe-
less, these subjects are likely to progress to AD. In community-
based studies, individuals withMCI are about 3 times more likely
to develop AD than those without cognitive impairment, and this
rate is somewhat higher in persons with amnestic MCI (Petersen
et al., 2001; Grundman et al., 2004, 2006). Other hypothetical
presentations ofMCIwith slight impairments at multiple domains
may progress to AD or VD, and those with single non-memory
domain impairment might progress to frontotemporal dementia,
Lewy body dementia, VD, primary progressive aphasia or
Parkinson.s disease besides AD (Petersen et al., 2001; Dubois
and Albert, 2004). Bennett et al. (2005) reported that in MCI
several pathological findings similar to that of AD or cerebral
infarctions were present and thus concluded that MCI might be
the earliest clinical manifestation of age-related neurological
diseases.
For clarity's sake, amnestic MCI is recommended to be used
with its operational criteria, including (1) memory complaint,
corroborated by an informant; (2) abnormal memory function;
documented by delayed recall; (3) normal general cognitive
function based on Clinical Dementia Rating (CDR) (Leonard,
1988) and Mini Mental State Examination (MMSE) (Folstein
et al., 1975); (4) none orminimal impairments in activities of daily
living (ADL); (5) not sufficiently impaired cognitively and
functionally to meet NINCDS-ADRDA criteria for AD.
Several cognitive tests were applied both to MCI and AD
patients to determine the specific cognitive dysfunctions in each
pathology. Verbal learning and delayed recall tests proved to bePlease cite this article as: Égerházi A et al. Automated Neuropsychological Test B





useful for the detection of preclinical AD and MCI (Estevez-
Gonzalez et al., 2003; Ivanoiu et al., 2005; Alladi et al., 2006),
as well as several visual or other cognitive tasks, such as visual
recognition, visuoconstructional performance, and semantic
fluency (Malloy et al., 2003; Barbeau et al., 2004; Ribeiro et al.,
2006).
Computerized neurocognitive batteries have been used in the
evaluation of cognitive impairments both among AD and MCI
patients. In MCI, dysfunctions were reported in memory,
executive function, visual spatial skills, processing speed and
cognitive flexibility (Dwolatzky et al., 2004; Gualtieri and
Johnson, 2005).
The aim of our study was to compare cognitive dysfunctions
in AD and MCI by a mean of a computerized test battery which
may provide more objective results in the individual test than
the classical neurocognitive tests. Furthermore, the computer-
ized battery is language independent and also, as a visual test, it
can be a useful tool to measure cognitive functions in patients
with mild aphasia. The hypothesis was that the performance
deficits of AD and MCI patients on the Cambridge Neuropsy-
chological Automated Test Battery (CANTAB) might be
similar, as MCI patients may already be in early stages of
Alzheimer's disease. In early AD, novel therapeutic interven-
tions are aimed at slowing the progression of the impairments
and at delaying the onset of disability; thus, there is an increased
need for diagnostic markers which may predict AD reliably.
2. Methods
2.1. Patient population
Two patients groups were entered into the study: dementia
patients and non-demented patients with amnestic MCI. A
detailed clinical examination was performed on all patients
including cranial computed tomography (CT) or magnetic
resonance imaging (MRI). The first patient group consisted of
15 demented patients (7 men, 8 women) with the diagnosis of
probable dementia of Alzheimer type (AD) according to criteria
of NINCDS-ADRDA and DSM-IV. The mean age (±SD) of the
subjects was 58±6 years (range: 42–83) (Table 1). The
diagnosis was based on the history of the patients and on
detailed physical, neurological and psychiatric examinations.
All demented patients had morphological changes in the brain
characteristic of AD, such as cerebral atrophy, especially in the
temporo-mesial region. The diagnosis was also confirmed by
the Ischemic Score of Hachinski (all patients with scores ≤4).
Severity of dementia was assessed by MMSE and the average
MMSE score (±SD) of the demented group was 21±1.2.
The second group consisted of 25 patients with MCI (12

















































































































physical disorders. The mean age (±SD) of the subjects was
55±6 years (range: 46–86) (Table 1). No significant
differences were found between the groups in age, gender
and education level. The patients had “amnestic MCI” as
described above according to the criteria of Petersen, and
CDR was 0.5 for all of them (Leonard, 1988). Psychiatric
examination revealed mild short-term memory loss, but the
symptoms were insufficient for the diagnosis of dementia
according to the criteria of the DSM-IV. Mini Mental State
Examination (MMSE) scores in all cases were higher than 26.
CT/MRI results were normal. Patients were not receiving any
medication. They were informed about the aim of the study
and gave their consent to participation. The study was carried
out according to the Helsinki Declaration.
2.2. Study design and assessment
Subjects were asked to perform a series of 13 computerized
neuropsychological tests of the Cambridge Neuropsychological
Test Automated Battery (CANTAB, Cambridge Cognition,
Cambridge, United Kingdom). CANTAB has been used and
proved to be a useful tool to assess cognitive functions in
diverse neurological and psychiatric disorders, such as
dementia, schizophrenia, depression, Parkinson's Disease (De
Jager et al., 2005; Bartók et al., 2005; Weiland-Fiedler et al.,
2004; Foltynie et al., 2003).
Subjects were seated at a comfortable height, approximate-
ly 0.5 m from the monitor, and were instructed to carry out the
tasks by touching the screen. After an initial explanation and
completing a simple “motor screening task” successfully
(touching the centre point of flashing crosses on the screen),
subjects were given the following tests in the following order
(the technical description of the tests can be found on the
Cambridge Cognition's website: http://www.cantab.com): Big
Little Circle (BLC): a two-stimuli visual discrimination and
category achievement test. Spatial working memory (SWM):
this task assesses the subject's ability to retain spatial
information and to manipulate remembered items in working
memory. Reaction time (RTI): The task is designed to measure
the subject's speed of response to a visual target where the
stimulus is either predictable (simple reaction time) or
unpredictable (choice reaction time). Spatial span (SSP): A
computerized version of the Corsi blocks, a test of span for
spatial items similar to ‘digit span’ tests for verbal items.
Pattern recognition memory (PRM): A test of visual
recognition memory in a 2-choice forced discrimination
paradigm. Spatial recognition memory (SRM): This task
tests visual spatial memory in a 2-choice forced discrimination
paradigm. Paired associate learning (PAL): Assessment of
simple visual pattern and visuospatial associative learning,
which contains aspects of both a delayed response procedure
and a conditional learning task. Intra/Extradimensional shift
task (IED): A test of rule acquisition and reversal, featuring
visual discrimination and attentional set shifting and analogous
to a category change in the Wisconsin Card Sorting Test.
Match to sample visual search (MTS): A two-stimuli visual
discrimination and category achievement test. DelayedPlease cite this article as: Égerházi A et al. Automated Neuropsychological Test B





matching to sample (DMS): This task tests visual memory
in a 4-choice delayed recognition memory paradigm. Stock-
ings of Cambridge (SOC): The task is analogous to the ‘Tower
of London’ test and assesses the subject's ability to engage in
spatial problem solving. This test makes substantial demands
on executive function. Rapid Visual Information Processing
(RVP): It is a visual continuous performance task, using digits
rather than letters. Results were compared to the internal
normative database of CANTAB, involving 3.000 healthy
volunteers, and were matched for age-groups and gender.
CANTAB tests were previously validated among Hungarian
healthy volunteers showing no statistically significant differ-
ences in the cognitive performance compared to the internal
normative database (Bartók et al., 2001).
2.3. Data analysis
Since no control group was available, the participants' Z-
scores of all CANTAB subtest results were calculated from
median scores on the basis of the normative database of 3,000
healthy volunteers. The index scores of the patients and those of
the normative database were compared using a one-tailed non-
parametric t-test. Statistical calculations were carried out using
the GraphPad Prism 4.00 for Windows software (GraphPad
Software, San Diego, CA, USA, http://www.graphpad.com)
and Pb0.05 was considered as significant.
3. Results
On all measures, the AD group performed significantly
poorer than the healthy individuals or the MCI group, as shown
in Fig. 1. The results of the individual tests for the two groups
are given in Table 2.
4. Discussion
The present results show that several cognitive domains are
already impaired in patients with MCI, and in AD patients
several other cognitive domains show impairment and the
severity of the cognitive dysfunctions is more pronounced.
Visual Paired Associate Learning (PAL test) was signifi-
cantly (Pb0.05) impaired among subjects with AD and MCI. A
successful performance in the PAL test requires both the
elaboration of “frontal strategies” and the “mnemonic process-
es” of the medial temporal lobe (Jakala et al., 1999). MCI
patients performed poorly on this test, as did AD patients, which
may suggest that they may already be in the early stages of the
disease. Several studies, including functional brain imaging
experiments, have shown a dysfunction of the medial temporal
lobe in the early phase of dementia and schizophrenia
(Antonova et al., 2004; Twamley et al., 2006). Furthermore,
elderly subjects with major depression also perform poorly on
tests of memory, as do AD subjects (Lichtenberg et al., 1995);
thus, the specificity of such tests is particularly crucial for being
able to differentiate AD individuals. Refinement of the sensi-
tivity of neuropsychological tests would allow possible disease-













































































The median Z-scores of the CANTAB tests compared to healthy individuals in
the AD group (n=15) and MCI group (n=25) t2:2











−7.196 b0.05 −2.942 b0.001
t2:6Spatial recognition
memory (SRM)
−2.201 b0.001 −2.061 b0.001
t2:7Spatial working
memory (SWM)
−0.968 b0.01 −0.8871 b0.001
t2:8Rapid visual
processing (RVP)
−2.735 b0.001 −2.101 b0.001
t2:9Spatial span (SSP) −1.212 b0.01 −0.755 b0.001
t2:10Stocking of
Cambridge (SOC)
−0.5713 n.s. −0.2675 n.s.
t2:11Matching-to-sample
(MTS)
−4.103 b0.05 −0.2235 n.s.
t2:12Reaction time (RTI) −1.109 b0.01 −4.520 n.s.
t2:13Pattern recognition
memory (PRM)
−1.942 b0.01 −0.3715 n.s.
t2:14Delayed matching to
sample (DMS)
−2.641 b0.001 −1.111 b0.05
n.s.=not significant. t2:15
Fig. 1. The pattern of median Z-scores of the CANTAB test and their difference
from the control scores among subjects with AD (n=15) and with MCI (n=25).
Significance: ⁎=Pb0.05, ⁎⁎=Pb0.01, ⁎⁎⁎=Pb0.001 compared to healthy
individuals.





neuronal loss (Blesch et al., 1998). The PAL task involves
learning an association between visual stimuli and distinct
spatial locations on a trial-by-trial basis, which has been
demonstrated to decline with age in factor-analytic studies
involving large samples (Robbins et al., 1994; Rabbitt and
Lowe, 2000). Sahakian and co-workers further demonstrated
impaired performance in groups diagnosed with probable AD
(Sahakian et al., 1990; Sahgal et al., 1991). Gould and co-
workers studied whether the same cognitive processes are in
operation when a task is performed at an 80% success level,
compared to a 20% success level. They found a differential
pattern of activity, which may reflect the use of different
mnemonic strategies across the two groups or, alternatively, it
may reflect a functional compensation for neuropathological
changes associated with Alzheimer's disease (Gould et al.,
2005). Fowler and co-workers reported that a 6-month decline
in the PAL performance of patients with mild cognitive
symptoms predicts later progression to AD (Fowler et al.,
1997, 2002). The poor performance shown by patients with
questionable dementia in the PAL test may be the result of a loss
of muscarinic cholinergic receptors and/or to an impairment of
the cholinergic neurotransmission in the parahippocampal
region (Fowler et al., 2002; Taffe et al., 2004).
The performance of both AD and MCI patients was
substantially impaired in the delayed matching to sample
(DMS). The delayed matching to sample test mainly assess the
cognitive functions of the temporal regions, a locuswell-known to
be involved early in the pathology of Alzheimer's disease
(Twamley et al., 2006). A significant impairment was also found
in the rapid visual processing (RVP) test as well, which suggests
the impairment of sustained attention. Though it is primarily a test
of visual sustained attention, it also requires both selective
attention and working memory for successful execution. The
impairment of these cognitive domains is well documented in
Alzheimer's disease (Rizzo et al., 2000; Jackson and Owsley,
2003). The spatial span (SSP) test, like the spatial working
memory (SWM) task, is sensitive toworkingmemory impairment
and thus to frontal lobe functions (Owen et al., 1995); in the
present study both MCI and AD patients had dysfunction in this
domain. The spatial recognition memory (SRM) task perfor-
mance, involving the neural systems of the medial temporal,Please cite this article as: Égerházi A et al. Automated Neuropsychological Test B





inferotemporal and several frontal regions was also significantly
impaired in both patient groups (Johnsrude et al., 1999).
AD, but not MCI, patients had a significant impairment in
two attentional tasks: matching-to sample (MTS), reaction
time (RTI) tasks, and in the pattern recognition memory (PRM)
test, involving the activity of posterior brain regions (Owen
et al., 1995) which may suggest that these cognitive domains
are better preserved in the earliest phase of AD. In the present
study we were unable to find any significant impairment in a
test of executive function (Stockings of Cambridge— SOC) in
both AD and MCI patient group. As executive dysfunction is
usually present in the early stages of AD (Arnaiz and
Almkvist, 2003; Twamley et al., 2006), this negative result
may be related to the younger age of both AD and MCI
patients in the present study.
Long before the onset of clinical dementia, neuropatholog-
ical changes are already present in mesial temporal regions
(hippocampal formations, parahippocampal gyrus, and entorh-
inal cortex), areas critical for long-term episodic memory
(Dubois and Albert, 2004). Amnestic mild cognitive impair-
ment (MCI) may be a prodromal state for Alzheimer's disease.
While the diagnosis of MCI is ultimately based on clinical
judgement, it may be supported by self-reported difficulties,
informants' reports about memory loss problems, and impaired
psychometric test performances. In the present study CANTAB
was used to compare cognitive deficits in a group of AD and
MCI patients in order to assess whether CANTAB can be a
useful tool to detect the early stages of Alzheimer's dementia.
The obtained results support previous findings that both AD and
MCI patients had a significantly impaired performance in the
Paired Associate Learning (PAL) test, showing a dysfunction of
the medial temporal lobe (Blackwell et al., 2004; Ribeiro et al.,











































































































































groups may suggest that the impaired performance in the PAL
test can serve as a marker for preclinical Alzheimer's disease,
and thus could be a useful tool to detect AD and also an
objective marker for the initiation of treatment in an early phase
of the development of AD. As several other domains were also
affected in MCI, further studies would help to characterize the
cognitive dysfunction profile in preclinical AD, which could
provide a more sensitive and specific approach to the early
detection and monitoring of progress of the disorder.
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